贝迪诺恩荣膺2022年度TOP 10 CRO大奖
近期，国际知名杂志《Pharma Tech Outlook》颁发”TOP 10 CRO IN APAC 2022″，此奖旨在表彰亚太地区为医疗领域做出卓越贡献的CRO企业。贝迪诺恩荣幸获得《Pharma Tech Outlook》和国际行业专家的认可，成为TOP 10 CRO IN APAC 2022。
Tracy Yu, 贝迪诺恩美国公司总经理接受《Pharma Tech Outlook》采访：
As a one-stop shop, we take care of all necessities during the entire life cycle of a medical device in China for our clients. As a consulting firm, BradyKnows assists its clients with quality assurance (QA) and post-market surveillance (PMS). During the pre-market phase, the company ensures that its clients’ quality management systems (QMS) comply with the requirements declared by the Chinese authorities. A manufacturer outside China may abide by the FDA or the EU requirements, so BradyKnows performs a gap analysis to accurately determine the documents the client should provide to the National Medical Products Administration (NMPA) and verifies that their QMS complies. During the post-market phase, BradyKnows further helps its clients to stay compliant with those requirements by performing adverse events reporting or annual safety reporting called the periodic risk evaluation report (PRER).
《Pharma Tech Outlook》是国际知名医药类技术杂志，在亚太地区有超过76000名用户，为医药行业专家、企业决策者分享他们在产品、服务、制药技术趋势等方面的看法、经验和优质资源提供平台。该杂志致力于提供全面和详细技术领域信息和前沿观点，促进创新转化为服务。
更多内容，详见BradyKnows Medical – CRO APAC Solutions/Service Company (pharmatechoutlook.com)